Mechanisms of disease: Leukotrienes and lipoxins in scleroderma lung disease - Insights and potential therapeutic implications

Nature Clinical Practice Rheumatology

Volumn 3, Issue 1, 2007, Pages 43-51

  Kowal Bielecka, Otylia ^a   Kowal, Krzysztof ^a   Distler, Oliver ^b   Gay, Steffen ^c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; LEUKOTRIENE; LEUKOTRIENE A4; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXIN; PREDNISONE; ZILEUTON;

CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CHRONIC INFLAMMATION; COLLAGEN SYNTHESIS; FIBROBLAST; FIBROSING ALVEOLITIS; HUMAN; INFLAMMATORY INFILTRATE; INTERSTITIAL LUNG DISEASE; LEUKOCYTE ACTIVATION; LOW DRUG DOSE; LUNG ALVEOLITIS; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; LUNG LAVAGE; LYMPHOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; UPREGULATION;

CELL PROLIFERATION; COLLAGEN; EICOSANOIDS; HUMANS; INFLAMMATION; LEUKOTRIENES; LIPOXINS; LUNG DISEASES, INTERSTITIAL; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC;

EID: 33846983537     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0375     Document Type: Review

References (59)

1. White B (2003) Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 29:371-390
2. Thannickal VJ et al. (2004) Mechanisms of pulmonary fibrosis. Annu Rev Med 55: 395-417
3. Samuelsson B et al. (1987) Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 237:1171-1176
4. Henderson WR (1994) The role of leukotrienes in inflammation. Ann Intern Med 121:684-697
5. Serhan CN (2005) Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 73: 141-162
6. Koyama S et al. (1998) Human lung fibroblasts release chemokinetic activity for monocytes constitutively. Am J Physiol 275: L223-L230
7. Palmantier R et al. (1991) Thrombin-activated platelets promote leukotriene B4 synthesis in polymorphonuclear leucocytes stimulated by physiological agonists. Br J Pharmacol 103: 1909-1916
8. Fiore S et al. (1990) Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J Exp Med 172:1451-1457
9. Schonfeld W et al. (1988) Leukotriene generation and metabolism in isolated human lung macrophages. Immunology 65:529-536
10. Levy BD et al. (1993) Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J Clin Invest 92:1572-1579
11. Nasser GM et al. (1994) Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J Biol Chem 269:27631-27634
12. Profita M et al. (2002) Leukotriene B4 production in human mononuclear phagocytes is modulated by interleukin-4-induced 15-lipoxygenase. J Pharmacol Exp Ther 300:868-875
13. Levy BD et al. (2001) Lipid mediator class switching during acute inflammation: Signals in resolution. Nat Immunol 2: 612-619
14. Peters-Golden M et al. (2005) Leukotrienes: Underappreciated mediators of innate immune responses. J Immunol 174: 589-594
15. Tager AM et al. (2003) Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 4:982-990
16. Prinz I et al. (2005) The type 1 cysteinyl leukotriene receptor triggers calcium influx and chemotaxis in mouse alpha beta- and gamma delta effector T cells. J Immunol 175:713-719
17. Brink C et al. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 55:195-227
18. Gronert K et al. (2001) Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol 158:3-9
19. Serhan CN et al. (2003) Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 171:6856-6865
20. Mensing H et al. (1984) Leukotriene B4 induces in vitro fibroblast chemotaxis. J Invest Dermatol 82:9-12
21. Baud L et al. (1987) Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: Effect of indomethacin. J Immunol 138:1190-1195
22. Phan SH et al. (1988) Binding of leukotriene C4 to rat lung fibroblasts and stimulation of collagen synthesis in vitro. Biochemistry 27: 2846-2853
23. Perng DW et al. (2006) Leukotriene C4 induces TGF-beta1 production in airway epithelium via p38 kinase pathway. Am J Respir Cell Mol Biol 34: 101-107
24. Peters-Golden M et al. (2002) Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 165:229-235
25. Beller TC et al. (2004) Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc Natl Acad Sci USA 101:3047-3052
26. Vargaftig BB et al. (2003) Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. Am J Respir Cell Mol Biol 28:410-419
27. Kolodsick JE et al. (2004) Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 172:4068-4076
28. Beller TC et al. (2004) Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 279: 46129-46134
29. McMahon B et al. (2002) Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J 16:1817-1819
30. Sato Y et al. (2004) Down-regulation of lipoxin A4 receptor by thromboxane A2 signaling in RAW246.7 cells in vitro and bleomycin-induced lung fibrosis in vivo. Biomed Pharmacother 58:381-387
31. Wu SH et al. (2006) Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor. Am J Respir Cell Mol Biol 34:65-72
32. Mitchell D et al. (2004) Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells. Am J Pathol 164: 937-946
33. McMahon B et al. (2000) Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J Biol Chem 275: 27566-27575
34. Wu SH et al. (2005) Lipoxin A4 inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells. Kidney Int 68: 35-46
35. Wu SH et a/. (2005) High dose of lipoxin A4 induces apoptosis in rat renal interstitial fibroblasts. Prostaglandins Leukot Essent Fatty Acids 73:127-137
36. Rodgers K et al. (2005) Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am J Pathol 167: 683-694
37. Wu SH et al. (2006) Lipoxin A4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells. Kidney Int 69: 248-256
38. Vachier I et al. (2005) Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 115:55-60
39. Kowal-Bielecka O et al. (2003) Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. Arthritis Rheum 48:1639-1646
40. Silver RM et al. (1990) Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 88:470-476
41. Wilborn J et al. (1996) Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 97: 1827-1836
42. Kowal-Bielecka O et al. (2005) Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann Rheum Dis 64: 484-486
43. Witt C et al. (1999) Pulmonary involvement in diffuse cutaneous systemic sclerosis: Bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 58:635-640
44. White B et al. (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947-954
45. Kowal-Bielecka O et al. (2005) Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: A retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 64:1343-1346
46. Goldstein RA et al. (1990) Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis 142:481-486
47. Kowal-Bielecka O et al. (2001) Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: A newly identified pathway to skin inflammation in systemic sclerosis. Arthritis Rheum 44: 1865-1875
48. Huang L et al. (2GO4) Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol 24: 1783-1788
49. Ichiyama T et al. (2005) Cysteinyl leukotrienes induce monocyte chemoattractant protein 1 in human monocytes/macrophages. Clin Exp Allergy 35:1214-1219
50. Meloni F et al. (2004) BAL cytokine profile in different interstitial lung diseases: A focus on systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis 21:111-118
51. Distler O et al. (2001) Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 44:2665-2678
52. Distler JH et al. (2006) Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 54:214-225
53. Kowal-Bielecka O et al. (2005) Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: An imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 52: 3783-3791
54. Flaherty KR et al. (2004) Zileuton versus azathioprine/prednisone in idiopathic pulmonary fibrosis. Europ Respir J 24 (Suppl 48): S254
55. Petasis NA et al. (2005) Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot Essent Fatty Acids 73: 301-321
56. Tager AM et al. (2003) BLT1 and BLT2: The leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids 69: 123-134
57. Qiu H et al. (2006) Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. Proc Natl Acad Sci USA 103:6913-6918
58. Kanaoka Y et al. (2004) Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 173: 1503-1510
59. Uzonyi B et al. (2006) Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc Natl Acad Sci USA 103:6326-6331